港股异动 | 李氏大药厂(00950)尾盘涨超21% 上半年纯利增长7.5% 旗下PD-L1单抗国内近日获批上市

智通财经
Sep 01

智通财经APP获悉,李氏大药厂(00950)尾盘涨超21%,截至发稿,涨16.02%,报21港元,成交额3195.61万港元。

消息面上,李氏大药厂此前发布中期业绩,该集团取得收益6.95亿港元,同比增加5.5%;主要由集团产品组合稳健的销售表现所带动。2025年上半年的公司拥有人应占纯利为6718.5万港元,同比增加7.5%。此表现加强去年确立的可持续增长轨迹,并反映集团进一步巩固营运实力及财务纪律。每股盈利11.41港仙。

值得注意的是,李氏大药厂7月底公告称,旗下子公司兆科肿瘤申报的抗PD-L1单克隆抗体索卡佐利单抗新适应症上市申请已获得批准。根据李氏大药厂公开资料可知,该药本次获批的适应症为联合化疗一线治疗广泛期小细胞肺癌。此举标志着索卡佐利单抗注射液继最初有条件获批用于治疗复发或转移性子宫颈癌后第二个获批准的适应症。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10